To include your compound in the COVID-19 Resource Center, submit it here.

Sotatercept: Phase II/III started

Celgene began a 2-part, U.S. Phase II/III trial in about 840 patients. The single-blind, dose-ranging Phase IIa

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE